Market Overview

NetworkNewsBreaks – Trxade Group, Inc. (NASDAQ: MEDS) (OTCQB: TRXD) Announces Nasdaq Uplisting, Pricing of $5.2M Firm Commitment Public Offering, Effectiveness of Reverse Stock Split

Share:

Trxade Group (NASDAQ:MEDS) (OTCQB:TRXD), an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals, this morning announced that its common stock will today begin trading on the Nasdaq Capital Market under the new symbol ‘MEDS'. In connection with the company's […]

Trxade Group (NASDAQ:MEDS) (OTCQB:TRXD), an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals, this morning announced that its common stock will today begin trading on the Nasdaq Capital Market under the new symbol ‘MEDS'. In connection with the company's uplisting, Trxade's common stock will cease trading on the OTCQB. In addition, Trxade Group also announced the pricing of a firm commitment public offering of 806,452 shares of its common stock at a price to the public of $6.50 per share. Trxade Group granted a 45-day option to the underwriters to purchase up to an additional 120,967 shares of common stock to cover overallotments, if any. Trxade Group expects to secure gross proceeds of $5.2 million from the sale of common stock in the offering, which is expected to close on or about February 18, 2020, subject to customary conditions.

To view the full press release, visit http://nnw.fm/4Ix3s

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. (NASDAQ:MEDS) is an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased profit margins to healthcare buyers and sellers of pharmaceuticals. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms; the Trxade B2B trading platform with 11,900 registered pharmacies, licensed virtual Wholesale and Mail Order Pharmacy delivery capabilities using DelivMeds app. For additional information, please visit www.Trxade.com.

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company's newsroom at http://nnw.fm/TRXD

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com